European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
We are inviting expressions of interest to join a Clinical Endoscopists Working Group
We are keen to give our clinical endoscopist members a louder voice within the BSG. Could you represent regional colleagues on issues important to you, including workforce, training, education and research?
Congratulations to our new Deputy Chair Education, Dr Sophia Than
Congratulations to our new Deputy Chair Education, Dr Sophia Than
Congratulations to our new Deputy Guidelines Lead, Prof Anjan Dhar
We are delighted to welcome Prof Anjan Dhar as a BSG Officer and Deputy Guidelines Lead (2025-2027)!